IRCT20200105046010N51招募中未知
in- Vivo Bioequivalence study of Erlotinib tablet 150 mg Abidi Pharma (LOTIVA® 150 mg) with brand drug (TARCEVA® 150 mg, Rosche, Switzerland) in Iranian healthy volunteers.
Abidi Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health
- •Body mass index between18-28
- •Informed consent
- •Being at the age of 18-55 years old
排除标准
- •A history of cardiovascular disease
- •A history of liver & kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity to the drug
研究者
相似试验
招募中
不适用
In-vivo Bioequivalence Test of Erlotinib tablets with brand drug (TARCEVA® 150 mg, Rosche, Switzerland)IRCT20200105046010N46Actero Pharma. Co.24
已完成
不适用
Bioequivalence study of erlotinib 150 mgIRCT20200623047902N6Zistdaru Danesh Company24
尚未招募
不适用
In-vivo Bioequivalence Test of NEORAPA® tablet with brand drugs (AFINITOR® 10mg Novartis).In this study, the disease is not examined. Subject bioequivalence test and reference tablets Everolimus studied..IRCT20200105046010N24ABIDI Pharmaceutical Company24
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet with brand drugs (AFINITOR® 10mg Novartis).IRCT20200105046010N44SOBHAN ONCOLOGY Pharmaceutical CO.24
招募中
不适用
In-vivo Bioequivalence Test of Everolimus tablet (ROLIMA® 0.75 mg) with brand drugs (CERTICAN® 0.75 mg, Novartis,Switzerlan).IRCT20200105046010N58anoalvand Pharmaceutical Co.24